Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ulcer 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Sarcoma 1Ovarian Neoplasms 1Lymphatic Metastasis 1Hemangioma, Capillary 1Fallopian Tube Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Oxaliplatin 14Leucovorin 12Fluorouracil 12Cetuximab 10Bevacizumab 9pembrolizumab 7Specimen Handling 7Nivolumab 6Magnetic Resonance Spectroscopy 6Irinotecan 5encorafenib 4Pemetrexed 4Gemcitabine 4Cisplatin 4Capecitabine 4fludarabine 3cemiplimab 3Laparoscopy 3Folfox protocol 3Early Intervention, Educational 3Cyclophosphamide 3Carboplatin 3Biopsy 3trifluridine tipiracil drug combination 2pertuzumab 2durvalumab 2dehydroftorafur 2aldesleukin 2X-Rays 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × Propranolol × 90 days × Clear all
NCT07549906 2026-04-24

Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study

Sun Yat-sen University

Phase 2 Not yet recruiting
45 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡